The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel.

Abstract

BACKGROUND The optimal treatment strategy for elderly patients with advanced nonsmall cell lung carcinoma has not been defined to date. The authors performed a retrospective analysis of a Phase III trial that treated patients who had Stage IIIB or IV nonsmall cell lung carcinoma with carboplatin and paclitaxel and analyzed the impact of age on response rate… (More)

Topics

Cite this paper

@article{Hensing2003TheIO, title={The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel.}, author={Thomas A. Hensing and Amy H. Peterman and Michael J. Schell and Ji-Hyun Lee and Mark A. Socinski}, journal={Cancer}, year={2003}, volume={98 4}, pages={779-88} }